
Weekly Roundup: January 3-7
ICYMI, this week we had stories on the continued issues with iPLEDGE, the new data on spesolimab treatment for GPP, and more.
Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.
New research has been published in the New England Journal of Medicine on spesolimab as a treatment for generalized pustular psoriasis.
But mask-wearing still vital to slowing spread of disease, agency says.
FUE is a type of hair transplant that requires physicians to change tools to accommodate different hair and scalp types. Now, a recent study highlights a single device aiming to treat all types of hair situations.
The new research will investigate many factors of the skin disease like changes over lifetime, new therapy pathways, and the science behind itch and inflammation.
Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.
Centering discussion on a case of plaque psoriasis, experts share their experience with patient counseling and selecting therapy.
In this week’s Pointers with Dr Portela, the 208SkinDoc had already called out the Green Mask Stick’s false advertising, but now the controversy continues.
The panel reviews therapeutic classes and their respective benefits in patients being treated for plaque psoriasis.
The Skin of Color Society released an article detailing its 2021 achievements, containing what the society considers its most active and successful year.
A survey conducted by Dermatology Times® found that many still cannot access the iPLEDGE system. Now some have created guides to get around the issue.
The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.
Skin sensitivity will be a factor in vehicles for new treatments.
Skin cancer dermoscopy is getting a hightech overhaul as the scope of innovation broadens from a singular focus on the stand-alone product to the development of a comprehensive medical, patient care, and workflow management platform.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















